eaa777cd_CER_Inventory___CER_Inventory__Category
[Agency] NIH [Project Title] COMPARATIVE EFFECTIVENESS: ERYTHROPOIETIC STIMULATING AGENTS IN TREATMENT OF MDS [Institution] UNIVERSITY OF MARYLAND BALTIMORE [Amount] $325,754 [Summary] Narrative Myelodysplastic syndromes (MDS) are the most common hematologic malignancy in the elderly, with at least 10,000 new cases diagnosed each year. Erythropoietic stimulating agents (ESA) are effective in treating the symptomatic anemia that affects MDS patients, but little is known about longer term positive and negative health effects of ESAs, compared to supportive care with repeated blood transfusions. In this study, we will use data from regional cancer registries that is linked to Medicare enrollment and insurance claims data. We will examine the characteristics of Medicare beneficiaries with MDS, patterns of treatment, safety and effectiveness of ESA use, and costs of care. [Completion/ Closing Date] 10/01/2010 [Link] link [Category] 
Medical treatments, items and services
CER Inventory | CER Inventory
Category